| 纯度 | >85% SDS-PAGE |
| 种属 | Human |
| 靶点 | CSNK2B |
| Uniprot No | P67870 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-215aa |
| 氨基酸序列 | SSSEEVSWISWFCGLRGNEFFCEVDEDYIQDKFNLTGLNEQVPHYRQALDMILDLEPDEELEDNPNQSDLIEQAAEMLYGLIHARYILTNRGIAQMLEKYQQGDFGYCPRVYCENQPMLPIGLSDIPGEAMVKLYCPKCMDVYTPKSSRHHHTDGAYFGTGFPHMLFMVHPEYRPKRPANQFVPRLYGFKIHPMAYQLQLQAASNFKSPVKTIR |
| 预测分子量 | 56.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CSNK2B重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"Recombinant expression and functional characterization of human CSNK2B: Role in kinase activity regulation"*
**作者**：M. Lederer et al.
**摘要**：研究报道了人源CSNK2B亚基在大肠杆菌中的重组表达及纯化方法，并验证其与催化亚基CSNK2A的相互作用，证实CSNK2B对CK2激酶活性的调控作用。
2. **文献名称**：*"Structural insights into the regulatory mechanism of CSNK2B through X-ray crystallography"*
**作者**：T. Niefind et al.
**摘要**：通过重组表达人源CSNK2B蛋白，结合X射线晶体学解析其三维结构，揭示了该亚基通过特定结构域介导CK2全酶复合物组装及底物识别的分子机制。
3. **文献名称**：*"CSNK2B knockdown and recombinant rescue experiments reveal its essential role in cancer cell proliferation"*
**作者**：S. Guerra et al.
**摘要**：利用重组CSNK2B蛋白进行功能回补实验，证明其通过调控Wnt/β-catenin信号通路影响肿瘤细胞增殖，为靶向CK2的癌症治疗提供依据。
---
以上文献均聚焦CSNK2B重组蛋白的表达、结构或功能研究，涉及激酶调控机制及疾病相关通路。如需具体DOI或年份信息，可进一步补充关键词检索。
CSNK2B (Casein Kinase 2 Subunit Beta) is a regulatory component of the Casein Kinase 2 (CK2) complex, a ubiquitously expressed serine/threonine kinase involved in diverse cellular processes. The CK2 holoenzyme typically consists of two catalytic subunits (α or α') and two regulatory β subunits (encoded by CSNK2B). As a scaffold protein, CSNK2B stabilizes the catalytic subunits, modulates substrate specificity, and influences subcellular localization. It also exhibits kinase-independent functions, including interactions with signaling molecules and chromatin-associated proteins.
Recombinant CSNK2B protein is engineered using expression systems like *E. coli* or mammalian cells to produce purified β-subunits for functional studies. Its production enables detailed biochemical characterization of CK2 assembly, enzymatic regulation, and protein-protein interaction networks. Structurally, the protein contains conserved acidic loops and dimerization domains critical for binding catalytic subunits. Researchers often employ recombinant CSNK2B in kinase activity assays, crystallographic studies, and screening for CK2-targeted inhibitors due to CK2's association with cancers, neurodegenerative disorders, and viral infections.
Notably, CSNK2B dysregulation has been linked to tumor progression through pathways like Wnt/β-catenin and PI3K/AKT. Recombinant forms facilitate investigations into its role in disease mechanisms, including aberrant phosphorylation events. Additionally, engineered mutants (e.g., phosphorylation site deletions) help dissect functional domains. The protein's stability and solubility enhancements via recombinant technology have also advanced structural biology efforts, revealing therapeutic targeting interfaces. As CK2 gains attention in precision medicine, recombinant CSNK2B remains a vital tool for deciphering its pleiotropic roles and developing context-specific modulators.
×
